A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease

被引:16
作者
Falloon, Katherine [1 ]
Cohen, Benjamin [1 ]
Ananthakrishnan, Ashwin N. [2 ]
Barnes, Edward L. [3 ]
Bhattacharya, Abhik [4 ]
Colombel, Jean-Frederic [4 ]
Cross, Raymond K. [5 ]
Driscoll, Marcia S. [6 ]
Fernandez, Anthony P. [7 ]
Ha, Christina [8 ]
Herfarth, Hans [3 ]
Horst, Sara [9 ]
Hou, Jason [10 ,11 ]
Husni, M. Elaine [12 ]
Kroshinsky, Daniela [13 ]
Kuhn, Kristine A. [14 ]
Lowder, Careen Y. [15 ]
Martin, George [16 ]
Parikh, Deep [17 ]
Sayed, Christopher J. [18 ]
Schocket, Lisa [19 ]
Siaton, Bernadette C. [20 ]
Vedak, Priyanka [18 ]
Weisman, Michael H. [21 ]
Rieder, Florian [1 ]
机构
[1] Cleveland Clin Fdn, Dept Gastroenterol & Hepatol, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA
[3] Univ N Carolina, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA
[4] Mt Sinai, Dept Gastroenterol, New York, NY USA
[5] Univ Maryland, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Baltimore, MD 21201 USA
[6] Univ Maryland, Dept Dermatol, Baltimore, MD 21201 USA
[7] Cleveland Clin Fdn, Dept Dermatol, Cleveland, OH 44195 USA
[8] Mayo Clin Arizona, Dept Gastroenterol, Scottsdale, AZ USA
[9] Vanderbilt Univ, Med Ctr, Dept Gastroenterol Hepatol & Nutr, Nashville, TN USA
[10] Baylor Coll Med, Ctr Innovat Qual Effectiveness & Safety IQuESt, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA
[11] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA
[12] Cleveland Clin Fdn, Dept Rheumatol & Immunol Dis, 9500 Euclid Ave, Cleveland, OH 44195 USA
[13] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA
[14] Univ Colorado, Div Rheumatol, Dept Med, Anschutz Med Campus, Aurora, CO USA
[15] Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[16] Dr George Martin Dermatol Associates, Kihei, HI USA
[17] New York Univ Langone Hlth, New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY USA
[18] Univ N Carolina, Dept Dermatol, Chapel Hill, NC 27515 USA
[19] Univ Maryland, Dept Ophthalmol, Baltimore, MD 21201 USA
[20] Univ Maryland, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA
[21] Stanford Univ, Sch Med, Dept Immunol & Rheumatol, Stanford, CA 94305 USA
关键词
PERIPHERAL SPONDYLOARTHRITIS; PYODERMA-GANGRENOSUM; DELPHI; INFLIXIMAB; PREVALENCE; RISK;
D O I
10.1111/apt.16853
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims Extra-intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half of the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, and treatment targets is limited. Methods As a starting point for a national EIM study network, an interdisciplinary expert panel of 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, and 4 patient representatives was assembled. Modified Delphi consensus methodology was used. Fifty-four candidate items were derived from the literature review and expert opinion focusing on five major EIMs (erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis) were rated in three voting rounds. Results For use in a clinical practice setting and as part of the creation of a prospective registry of patients with EIMs, the panel developed definitions for erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis; identified the appropriate and optimal subspecialists to diagnose and manage each; provided methods to monitor disease course; offered guidance regarding monitoring intervals; and defined resolution and recurrence. Conclusions Consensus criteria for appropriate and optimal means of diagnosing and monitoring five EIMs have been developed as a starting point to inform clinical practice and future trial design. Key findings include straightforward diagnostic criteria, guidance regarding who can appropriately and optimally diagnose each, and monitoring options that include patient and physician-reported outcomes. These findings will be used in a national multicenter study network to optimise the management of EIMs.
引用
收藏
页码:1179 / 1191
页数:13
相关论文
共 32 条
  • [1] Bernstein CN, 2001, AM J GASTROENTEROL, V96, P1116
  • [2] Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
    Brooklyn, TN
    Dunnill, MGS
    Shetty, A
    Bowden, JJ
    Williams, JDL
    Griffiths, CEM
    Forbes, A
    Greenwood, R
    Probert, CS
    [J]. GUT, 2006, 55 (04) : 505 - 509
  • [3] Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review
    Chateau, Thomas
    Bonovas, Stefanos
    Le Berre, Catherine
    Mathieu, Nicolas
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 (12) : 1569 - 1577
  • [4] AN EXPERIMENTAL APPLICATION OF THE DELPHI METHOD TO THE USE OF EXPERTS
    DALKEY, N
    HELMER, O
    [J]. MANAGEMENT SCIENCE, 1963, 9 (03) : 458 - 467
  • [5] EXPERIMENTAL STUDY OF GROUP OPINION - DELPHI METHOD
    DALKEY, N
    [J]. FUTURES, 1969, 1 (05) : 408 - 426
  • [6] Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease
    Dubinsky, Marla C.
    Cross, Raymond K.
    Sandborn, William J.
    Long, Millie
    Song, Xue
    Shi, Nianwen
    Ding, Yao
    Eichner, Samantha
    Pappalardo, Brandee
    Ganguli, Arijit
    Wang, Anthony
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (09) : 1876 - 1882
  • [7] Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysis
    Feagan, B. G.
    Sandborn, W. J.
    Colombel, J. -F.
    O'Byrne, S.
    Khalid, J. M.
    Brayshaw, N.
    Geransar, P.
    Rubin, D. T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S36 - S38
  • [8] Extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC
    Ghosh, S.
    Casellas, F.
    O'Shea, C.
    Leonard, M.
    Petersson, J.
    Peyrin-Biroulet, L.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S314 - S315
  • [9] Comparing face-to-face meetings, nominal groups, Delphi and prediction markets on an estimation task
    Graefe, Andreas
    Armstrong, J. Scott
    [J]. INTERNATIONAL JOURNAL OF FORECASTING, 2011, 27 (01) : 183 - 195
  • [10] Emerging treatment options for extraintestinal manifestations in IBD
    Greuter, Thomas
    Rieder, Florian
    Kucharzik, Torsten
    Peyrin-Biroulet, Laurent
    Schoepfer, Alain M.
    Rubin, David T.
    Vavricka, Stephan R.
    [J]. GUT, 2021, 70 (04) : 796 - 802